CORRECTION: Altimmune Q2 2024 GAAP EPS $(0.35) Misses $(0.34) Estimate, Sales $5.000K Down From $6.000K YoY
Portfolio Pulse from Benzinga Newsdesk
Altimmune (NASDAQ:ALT) reported Q2 2024 GAAP EPS of $(0.35), missing the $(0.34) estimate and showing a 9.37% increase in losses from the previous year. Sales were $5.000K, down 16.67% YoY.
August 08, 2024 | 11:23 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Altimmune reported Q2 2024 GAAP EPS of $(0.35), missing the $(0.34) estimate and showing a 9.37% increase in losses from the previous year. Sales were $5.000K, down 16.67% YoY.
Altimmune's Q2 2024 earnings report shows a larger-than-expected loss and a significant drop in sales compared to the previous year. This negative performance is likely to impact the stock price negatively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100